Castle Biosciences Inc
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report4 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+4.52%
vs ±15.4% implied · ×0.29
shaded = implied · ▲▼ = realized
SentenceOur revenue for our test reports provided for patients covered by Medicare as a percentage of total revenue, was 44% and 47% for the years ended December 31, 2025 and 2024, respectively.
basisCSTL FY2025 revenue $344M
CSTL 10-Kaccession 0001628280-26-012272
SentenceWe procure certain reagents, equipment, chips/cards and other materials used to perform our tests from sole suppliers such as ThermoFisher Scientific, Inc., Promega and Qiagen, Inc.
CSTL 10-Kaccession 0001628280-26-012272
SentenceIn June 2025, we entered into a collaboration and license agreement with SciBase Holding AB ("SciBase") to develop and commercialize diagnostic tests for dermatologic diseases, beginning with atopic dermatitis.
CSTL 10-Kaccession 0001628280-26-012272
SentenceFor example, we license certain intellectual property from WUSTL that is incorporated into DecisionDx-UM.
CSTL 10-Kaccession 0001628280-26-012272
SentenceAlthough we are an in-network participating provider with some commercial third-party payors, including several Blue Cross Blue Shield plans, and certain large, national commercial third-party payors, including Aetna, other commercial third-party payors have issued non-coverage policies that currently categorize our tests as experimental or investigational.
CSTL 10-Kaccession 0001628280-26-012272
SentenceAll of our MAAA tests, excluding our recently launched AdvanceAD-Tx test, have been granted Advanced Diagnostic Laboratory Test ("ADLT") status by the Centers for Medicare and Medicaid ("CMS") which means each test has demonstrated that (i) when combined with an empirically derived algorithm, it yields a result that predicts the probability a specific individual patient will develop a certain condition or conditions, or will respond to a particular therapy or therapies; and (ii) it provides new clinical diagnostic information that cannot be obtained from any other test or combination of tests.
CSTL 10-Kaccession 0001628280-26-012272
SentencePalmetto's MolDX program oversees MAAA tests that are reported from our Phoenix laboratory and Noridian is the MAC responsible for administering Medicare claims for test reports issued by our Phoenix laboratory.
CSTL 10-Kaccession 0001628280-26-012272
SentenceNovitas is the MAC responsible for administering Medicare claims for test reports issued by our Pittsburgh laboratory.
CSTL 10-Kaccession 0001628280-26-012272
SentencePalmetto issued a final expanded test-specific LCD for DecisionDx-Melanoma, effective November 22, 2020.
CSTL 10-Kaccession 0001628280-26-012272
SentencePalmetto's MolDX program oversees MAAA tests that are reported from our Phoenix laboratory and Noridian is the MAC responsible for administering Medicare claims for test reports issued by our Phoenix laboratory.
CSTL 10-Kaccession 0001628280-26-012272
SentenceFor example, we have a U.S. Federal Supply Schedule contract with the Veterans Health Administration covering tests with the exception of DecisionDx-UM.
CSTL 10-Kaccession 0001628280-26-012272
Castle Biosciences Inc
37.13
Castle Biosciences has 5 disclosed suppliers and 8 disclosed customers in SEC filings.
Expected move
No implied move.